Drug intelligence / Profile preview

EDG-003

Development stage: Preclinical
Lead developer: Edgewise Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

EDG-003 is an early-stage investigational drug candidate being developed by Edgewise Therapeutics for the treatment of cardiometabolic diseases. As of early 2024, the specific molecular target and modality of EDG-003 have not been publicly disclosed, although the program is part of Edgewise's expanding pipeline which traditionally focuses on small molecule modulators of the skeletal and cardiac sarcomere. The development of EDG-003 represents the company's strategic move into the cardiometabolic therapeutic area, leveraging its expertise in muscle physiology and biophysics.

Beyond the preview

Go deeper on EDG-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDG-003.

Explore the full profile